300 Participants Needed

Home Palliative Care for Dementia

CE
Overseen ByChristian Espino
Age: 65+
Sex: Any
Trial Phase: Academic
Sponsor: Icahn School of Medicine at Mount Sinai
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Home Palliative Care for Dementia?

Research suggests that palliative home care can improve the quality of care and reduce healthcare costs for older people with dementia at the end of life, indicating potential benefits of this treatment.12345

Is home palliative care safe for people with dementia?

The research does not provide specific safety data for home palliative care in dementia, but it suggests that this care model can improve the quality of care and support for patients and their families.13678

How is the Home Palliative Care treatment different from other treatments for dementia?

Home Palliative Care for dementia is unique because it focuses on providing holistic support to both the person with dementia and their family in their own home, addressing not just medical needs but also emotional and social aspects. This approach is different from traditional treatments that may focus more on medication and less on the overall well-being and quality of life of the patient and their family.19101112

What is the purpose of this trial?

A multi-site, single-blinded, parallel, randomized-controlled trial to evaluate the effectiveness of a novel model of in-home palliative care for dementia patients and their family caregivers. From inpatient and outpatient settings associated with four hospitals across New York City, patients with advanced dementia and their family caregivers will be randomized to intervention or augmented control.

Research Team

LP

Laura P Gelfman, MD, MPH

Principal Investigator

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

This trial is for patients over 64 years old with advanced dementia (GDS > 6) living in Manhattan, not in long-term care. They must have had a hospital visit within the last year and have a primary physician from one of the four Mount Sinai sites. A family caregiver must be willing to enroll and either patient or caregiver should speak English or Spanish.

Inclusion Criteria

I need help with daily activities like dressing or bathing.
Residence in Manhattan where they are currently living (not in a long-term care facility)
I have been hospitalized or visited the ER in the past year.
See 5 more

Exclusion Criteria

Does not have a family caregiver to enroll
Does not reside in Manhattan outside of long-term care facility
Does not have fluency in English or Spanish

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intake and Care Plan Development

An intake visit is conducted by the clinical team to develop a care plan based on clinical needs

1 week
1 visit (in-person or virtual)

Ongoing Monitoring and Support

Participants receive ongoing monitoring and support through telephone, video, and in-person visits, with access to a 24-hour advice line

12 months
Weekly IDT meetings, as needed visits

Follow-up

Participants are monitored for healthcare utilization and caregiver outcomes

12 months

Treatment Details

Interventions

  • Home Palliative Care
Trial Overview The study tests an innovative home palliative care model for those with advanced dementia. Participants are randomly assigned to receive this new care approach at home or an augmented standard control, comparing outcomes across multiple New York City hospitals.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Palliative care at homeExperimental Treatment1 Intervention
Randomized to intervention arm
Group II: Augmented controlActive Control1 Intervention
Randomized to augmented control (visits to the caregiver from a CHW without training in dementia or palliative care)

Home Palliative Care is already approved in United States for the following indications:

🇺🇸
Approved in United States as Home Palliative Care for:
  • Symptom management for advanced dementia
  • Support for family caregivers

Find a Clinic Near You

Who Is Running the Clinical Trial?

Icahn School of Medicine at Mount Sinai

Lead Sponsor

Trials
933
Recruited
579,000+

National Institute on Aging (NIA)

Collaborator

Trials
1,841
Recruited
28,150,000+

Findings from Research

In a study of 23,670 older people with dementia in Belgium, those who received palliative home care were significantly less likely to be hospitalized or undergo unnecessary medical tests in their final days, indicating improved quality of care.
Patients receiving palliative home care were more likely to die at home and had lower overall care costs in the last month of life, suggesting that this approach not only enhances the quality of end-of-life care but also reduces financial burdens.
Improved quality of care and reduced healthcare costs at the end-of-life among older people with dementia who received palliative home care: A nationwide propensity score-matched decedent cohort study.Miranda, R., Smets, T., De Schreye, R., et al.[2022]
The study developed the Palliative Support DEMentia Model (PalS-DEM), a prognostic tool that accurately predicts 1-year mortality in home-dwelling patients with advanced dementia, using data from 555 patients.
The model categorizes patients into low, moderate, and high-risk groups for mortality, helping healthcare providers identify those who may benefit from timely palliative care, with median survival times ranging from 19 to 175 days based on risk scores.
Prognostication in Home-Dwelling Patients with Advanced Dementia: The Palliative Support DEMentia Model (PalS-DEM).Hum, A., George, PP., Tay, RY., et al.[2021]
The Integrated Palliative Care Outcome Scale for People with Dementia (IPOS-Dem) shows variable inter-rating reliability among frontline staff in nursing homes, with kappa values indicating moderate to low agreement on individual items, suggesting the need for further refinement of the tool.
While the IPOS-Dem sum score demonstrated some dependability for research purposes, with a dependability index of .57, it still requires improvements in reliability and validity to be effectively used for decision-making in dementia care.
Inter-rating reliability of the Swiss easy-read integrated palliative care outcome scale for people with dementia.Spichiger, F., Volken, T., Larkin, P., et al.[2023]

References

Improved quality of care and reduced healthcare costs at the end-of-life among older people with dementia who received palliative home care: A nationwide propensity score-matched decedent cohort study. [2022]
Prognostication in Home-Dwelling Patients with Advanced Dementia: The Palliative Support DEMentia Model (PalS-DEM). [2021]
Inter-rating reliability of the Swiss easy-read integrated palliative care outcome scale for people with dementia. [2023]
Culture in the spotlight-cultural adaptation and content validity of the integrated palliative care outcome scale for dementia: A cognitive interview study. [2021]
A scoping review of the evidence for community-based dementia palliative care services and their related service activities. [2022]
Modelling the landscape of palliative care for people with dementia: a European mixed methods study. [2023]
Inpatients With Dementia Referred for Palliative Care Consultation: A Multicenter Analysis. [2022]
The challenge pathway: A mixed methods evaluation of an innovative care model for the palliative and end-of-life care of people with dementia (Innovative practice). [2022]
A comparison of four dementia palliative care services using the RE-AIM framework. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
The challenges of providing palliative care for older people with dementia. [2021]
A palliative approach to care of residents with dementia. [2019]
Palliative care for people with dementia living at home: A systematic review of interventions. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security